Cullen Capital trims Merck stake by 8.8% in third quarter
Alpha Vantage · MarketBeat · · AI-summarised by FinFlash
Cullen Capital Management cut its Merck & Co. stake by 8.8% in the third quarter, selling 178,420 shares while retaining over 1.8 million. Analysts still hold a "Moderate Buy" consensus with an average price target of Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.Understand the context